colistimethate sodium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
731 8068-28-8

Description:

MoleculeDescription

Synonyms:

  • colistimethate
  • colistimethate sodium
  • colistinmethanesulfonic acid
  • Colimycin M
  • Colimycin sodium methanesulfonate
  • colistin sulfomethate
  • colistin sodium methanesulfonate
  • pentasodium colistinmethanesulfonate
  • colistin sulphomethate
  • colobreathe
  • Molecular weight: 3485.59
  • Formula: C115H208N32Na10O56S10
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 706.71
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 4, 1970 FDA PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 203.38 36.72 44 1128 8773 63479077
Pathogen resistance 77.80 36.72 19 1153 6379 63481471
Multiple organ dysfunction syndrome 75.45 36.72 31 1141 56721 63431129
Hospitalisation 66.43 36.72 32 1140 85049 63402801
Acute kidney injury 56.22 36.72 43 1129 263372 63224478
Septic shock 48.76 36.72 24 1148 66605 63421245
Cystic fibrosis 46.28 36.72 11 1161 3285 63484565
Pseudo-Bartter syndrome 43.95 36.72 6 1166 73 63487777
Abscess neck 43.78 36.72 8 1164 665 63487185
Sepsis syndrome 41.10 36.72 8 1164 934 63486916

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 151.92 44.11 36 988 6765 34949142
Acute kidney injury 68.46 44.11 62 962 304926 34650981
Eosinophilia 63.12 44.11 25 999 26197 34929710
Leukocytosis 58.11 44.11 23 1001 24042 34931865
Hepatic cytolysis 53.81 44.11 19 1005 14477 34941430
Rash maculo-papular 47.80 44.11 21 1003 28430 34927477

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 236.54 33.35 57 2035 12794 79729502
Acute kidney injury 110.72 33.35 98 1994 519306 79222990
Pathogen resistance 106.36 33.35 31 2061 14311 79727985
Multiple organ dysfunction syndrome 75.51 33.35 44 2048 120202 79622094
Cystic fibrosis 70.18 33.35 17 2075 3863 79738433
Septic shock 69.43 33.35 42 2050 122759 79619537
Hospitalisation 68.61 33.35 38 2054 94198 79648098
Pseudo-Bartter syndrome 65.04 33.35 9 2083 83 79742213
Eosinophilia 49.42 33.35 24 2068 45321 79696975
Leukocytosis 47.36 33.35 23 2069 43432 79698864
Hepatic cytolysis 44.18 33.35 19 2073 27132 79715164
Rash maculo-papular 41.82 33.35 23 2069 56055 79686241
Sepsis syndrome 39.85 33.35 9 2083 1508 79740788
Lung transplant 38.88 33.35 11 2081 4550 79737746
Abscess neck 36.37 33.35 8 2084 1189 79741107
Condition aggravated 34.42 33.35 53 2039 501071 79241225

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0017217 Polymyxins
FDA EPC N0000175499 Polymyxin-class Antibacterial
CHEBI has role CHEBI:50266 Prodrugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection due to Escherichia coli indication 71057007
Pseudomonas Aeruginosa Infections indication
Klebsiella Infections indication
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis indication
Enterobacter Infection indication
Neuromuscular block, function contraindication 55394004
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Chickens Control of early mortality associated with Escherichia coli Indication

🐶 Veterinary products

ProductApplicantIngredients
First Guard Sterile Powder Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019694 VUID
N0000147786 NUI
D02049 KEGG_DRUG
12705-41-8 SECONDARY_CAS_RN
2708 RXNORM
4018653 VANDF
4019694 VANDF
C0110462 UMLSCUI
CHEBI:34650 CHEBI
CHEMBL507048 ChEMBL_ID
CHEMBL1201441 ChEMBL_ID
CHEMBL2304327 ChEMBL_ID
C004691 MESH_SUPPLEMENTAL_RECORD_UI
5642 INN_ID
XW0E5YS77G UNII
73897258 PUBCHEM_CID
DB01111 DRUGBANK_ID
41658 MMSL
4495 MMSL
d01113 MMSL
002805 NDDF
017469 NDDF
38686006 SNOMEDCT_US
422267005 SNOMEDCT_US
82885001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Colistimethate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 14789-201 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 21 sections
Colistimethate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 14789-201 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 21 sections
COLISTIMETHATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 23155-193 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 20 sections
COLISTIMETHATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 23155-193 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 20 sections
COLISTIMETHATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 23155-193 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 20 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 39822-0615 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 23 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 39822-0615 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 23 sections
Coly-MycinM HUMAN PRESCRIPTION DRUG LABEL 1 42023-107 INJECTION 150 mg INTRAMUSCULAR NDA 23 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 42023-131 INJECTION 150 mg INTRAMUSCULAR NDA AUTHORIZED GENERIC 23 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 45932-0023 INJECTION 150 mg INTRAMUSCULAR ANDA 22 sections
Colistimethate Human Prescription Drug Label 1 63323-393 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 12 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 70594-023 INJECTION, POWDER, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 24 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 70594-023 INJECTION, POWDER, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 24 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 70594-023 INJECTION, POWDER, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 24 sections